公开(公告)号：US20250002865A1

公开(公告)日：2025-01-02

申请号：US18704322

申请日：2022-10-27

Applicant: TOPPAN Holdings Inc. ,  OSAKA UNIVERSITY ,  KYOTO PREFECTURAL PUBLIC UNIVERSITY CORPORATION

Inventor： Shiro KITANO ,  Michiya MATSUSAKI ,  Fiona LOUIS ,  Yoshihiro SOWA

IPC: C12N5/071

Abstract: There is provided a method for producing a tissue construct comprising vascular endothelial cells, the method comprising incubating cells comprising at least adipose-derived stem cells from human in the presence of a TGFβ type I receptor inhibitor.

公开(公告)号：US20240402171A1

公开(公告)日：2024-12-05

申请号：US18815522

申请日：2024-08-26

Applicant: KYOTO PREFECTURAL PUBLIC UNIVERSITY CORPORATION ,  ACTUALEYES INC. ,  AURION BIOTECH, INC.

Inventor： Noriko Koizumi ,  Naoki Okumura ,  Hiroatsu Hirano ,  Shigeru Kinoshita ,  Morio Ueno

IPC: G01N33/569 ,  A61K35/30 ,  C12N5/079

Abstract: The purpose of the present invention is to provide a method of purification and preparation of cultured corneal endothelial cells, and in particular, to provide cell surface markers for use in corneal endothelial cells not including transformed cells. Provided are cell markers for distinguishing normal cells and transformed cells, in particular normal and transformed corneal endothelium cells. These cell markers relate to specific cell surface markers, for example, to a normal corneal endothelial surface marker such as CD166, and a transformed cell surface marker such as CD73. By using the transformed cell surface marker such as CD73 to remove transformed cells by sorting, it becomes possible to improve purity of a normal cultured corneal endothelium. By using normal corneal endothelial surface marker such as CD166, or by combined use with the transformed cell surface marker, it becomes possible to provide a means for verifying the purity of a prepared corneal endothelium.

公开(公告)号：US12029450B2

公开(公告)日：2024-07-09

申请号：US18266639

申请日：2021-11-29

Applicant: NITTO SEIKO CO., LTD. ,  KYOTO PREFECTURAL PUBLIC UNIVERSITY CORPORATION ,  Wook-Cheol Kim ,  NATIONAL UNIVERSITY CORPORATION UNIVERSITY OF TOYAMA

Inventor： Masakazu Ishihara ,  Yoshimitsu Ueno ,  Tomoaki Murata ,  Yukito Otsuki ,  Yusuke Kobayashi ,  Yoshinobu Oka ,  Wook-Cheol Kim ,  Tetsuo Aida ,  Sadami Tsutsumi

IPC: A61B17/58 ,  A61L31/02 ,  A61B17/00

CPC classification number: A61B17/58 ,  A61L31/022 ,  A61B2017/00004

Abstract: To ensure that a biodegradable medical implement dissolves in vivo at an appropriate dissolution rate. The biodegradable medical implement of the present invention is formed of a magnesium material, and, at least in one transverse section, a layer of magnesium crystal grains in which a (0001) plane in a hexagonal crystal structure is oriented toward a surface side is continuous over an entire circumference.

公开(公告)号：US20240215820A1

公开(公告)日：2024-07-04

申请号：US18553933

申请日：2022-03-31

Applicant: KYOTO PREFECTURAL PUBLIC UNIVERSITY CORPORATION ,  Rexxam Co., Ltd.

Inventor： Norihiko YOKOI ,  Jun KAWAI ,  Reiji YOSHIOKA ,  Ken-ichi YOSHIDA ,  Daichi YAMAMOTO

IPC: A61B3/10 ,  A61B3/14 ,  A61B5/00 ,  G06V10/764 ,  G16H30/40

CPC classification number: A61B3/101 ,  A61B3/14 ,  A61B5/4842 ,  G06V10/764 ,  G16H30/40

Abstract: Classifying dry eye syndrome using a measurement comprising a light-projecting unit projecting a predetermined pattern onto a cornea surface, an image capturing unit that repeatedly captures a reflected images of the pattern reflected off the cornea surface, an acquiring unit that acquires blurriness information according to a value indicating a blurriness level at a maximum portion of luminance values in a reflected image, for each of the captured multiple reflected images, and a classifying unit that acquires a classification result of a dry eye syndrome by applying multiple pieces of time-series blurriness information acquired by the acquiring unit to a learning model trained using multiple pairs of training input information. Providing a classification result of a dry eye syndrome corresponding to the training input information, and an output unit that outputs the classification result acquired by the classifying unit.

公开(公告)号：US12018283B2

公开(公告)日：2024-06-25

申请号：US16962190

申请日：2019-01-24

Applicant: KATAOKA CORPORATION ,  Kyoto Prefectural Public University Corporation

Inventor： Ping Dai ,  Yukimasa Takeda ,  Yoshinori Harada ,  Junichi Matsumoto ,  Ayumi Kusaka

IPC: C12N5/071

CPC classification number: C12N5/0676 ,  C12N2501/999 ,  C12N2506/1307

Abstract: The present invention chiefly aims to provide a process for directly inducing insulin-producing cells from somatic cells without performing artificial gene transfer. The present invention can include a process for producing an insulin-producing cell by inducing differentiation directly from a somatic cell, the process comprising a step of culturing the somatic cell in the presence of a cAMP inducer, and six members selected from the group consisting of a GSK3 inhibitor, a TGF-β inhibitor, a BMP inhibitor, a p53 inhibitor, a PI3K inhibitor, a Notch inhibitor and a RAR agonist, or all members thereof. The insulin-producing cells obtained by the present invention are useful in regenerative medicine and the like.

公开(公告)号：US20240067682A1

公开(公告)日：2024-02-29

申请号：US18025541

申请日：2021-09-16

Applicant: KYOTO PREFECTURAL PUBLIC UNIVERSITY CORPORATION ,  KYOTO SANGYO UNIVERSITY

Inventor： Masahiko SATO ,  Issei OHSHIMA ,  Tomoko HIRANO ,  Seisuke KIMURA

IPC: C07K14/435 ,  C12N15/82

CPC classification number: C07K14/43563 ,  C12N15/8262

Abstract: Disclosed are a partial peptide of cysteine-rich secretory protein, antigen 5, and pathogenesis-related 1 (CAP), consisting of an amino acid sequence of the conserved region of CAP, the peptide having at least one effect selected from the following effects: a plant stem cell-inducing effect, a plant environmental stress tolerance-enhancing effect, a plant pest resistance-inducing effect, a germination-promoting effect, a plant transformation efficiency-enhancing effect, and a plant growth-promoting effect; and a plant stem cell inducer, an environmental stress enhancer, a plant pest resistance inducer, a germination promoter, a transformation efficiency enhancer, and a plant growth promoter, all of which comprise the peptide.

公开(公告)号：US11733130B2

公开(公告)日：2023-08-22

申请号：US16310842

申请日：2017-10-05

Applicant: Umihira Co., Ltd. ,  Kyoto Prefectural Public University Corporation

Inventor： Kazuo Umihira ,  Keizou Ogino ,  Osamu Ukimura ,  Kazumi Kamoi

IPC: G01N1/04 ,  G01N1/28 ,  A61B10/02 ,  G01N1/06

CPC classification number: G01N1/04 ,  A61B10/02 ,  A61B10/0233 ,  A61B10/0275 ,  G01N1/06 ,  G01N1/28 ,  G01N2001/061

Abstract: A tissue dividing jig includes a tissue dividing base; and a cutting blade set provided with a cutting blade member and a guide portion, the tissue dividing base and the cutting blade set have a positioning mechanism that fixes their positions mutually, the cutting blade member is provided with a cutting blade extending in a longitudinal direction of the tissue placement portion, the guide portion guides the cutting blade member to move the cutting blade member to a fixed position on the tissue dividing base, and the cutting blade is disposed such that when the cutting blade set is disposed at a predetermined position on the tissue dividing base by the positioning mechanism and the cutting blade member is moved using the guide portion, the cutting blade divides the needle biopsy tissue on the tissue placement portion in the longitudinal direction.

公开(公告)号：US11624053B2

公开(公告)日：2023-04-11

申请号：US15100147

申请日：2014-11-26

Applicant: KYOTO PREFECTURAL PUBLIC UNIVERSITY CORPORATION ,  ActualEyes Inc. ,  CorneaGen, Inc.

Inventor： Noriko Koizumi ,  Naoki Okumura ,  Shigeru Kinoshita ,  Friedrich E. Kruse ,  Ursula Schloetzer-Schrehardt

IPC: C12N5/079 ,  A61K35/30

Abstract: The present invention provides a method of culturing corneal endothelial cells. More specifically, the present invention provides a composition for culturing or growing corneal endothelial cells, comprising at least one agent consisting of laminins and fragments thereof which express in corneal endothelial cells. Specifically, the present invention can comprise laminin 511 (alpha5 beta1 gamma1) and laminin 512 (alpha5 beta2 gamma 1). The present invention further provides a culture container for corneal endothelial cells, which is coated with the composition of the present invention. Furthermore, the present invention provides a method for culturing corneal endothelial cells comprising the step of using the composition or the container of the present invention to culture the corneal endothelial cells.

公开(公告)号：US20230057984A1

公开(公告)日：2023-02-23

申请号：US17936261

申请日：2022-09-28

Applicant: KYOTO PREFECTURAL PUBLIC UNIVERSITY CORPORATION ,  ActualEyes Inc. ,  CorneaGen, Inc.

Inventor： Shigeru KINOSHITA ,  Noriko KOIZUMI ,  Naoki OKUMURA

IPC: A61K35/30 ,  A01N1/02 ,  A61K31/713 ,  A61K31/4439 ,  C12N5/079 ,  A61K31/4709 ,  A61K31/4409 ,  A61K31/519 ,  C07K16/22 ,  C12N5/071

Abstract: The present invention provides a method for the normalized culturing of corneal endothelial cells. More specifically, the present invention provides a culture-normalizing-agent of a corneal endothelial cell, comprising a fibrosis inhibitor. In detail, the present invention provides a culture-normalizing agent comprising a transforming growth factor (TGF) β signal inhibitor. The present invention also provides a culture medium for culturing a corneal endothelial cell normally, which comprises the culture-normalizing agent according to the present invention and corneal endothelium culture components. The present invention also provides a method for culturing a corneal endothelial cell normally, comprising the step of culturing a corneal endothelial cell using the culture-normalizing agent according to the present invention or the culture medium according to the present invention.

公开(公告)号：US20220403002A1

公开(公告)日：2022-12-22

申请号：US17773241

申请日：2020-10-28

Applicant: KYOTO PREFECTURAL PUBLIC UNIVERSITY CORPORATION ,  MEDINET CO., LTD.

Inventor： Satoshi GOJO ,  Daisuke KAMI ,  Atsushi HOSHINO ,  Yoshito MINAMI ,  Akira SHIKUMA

IPC: C07K14/705 ,  C07K14/725 ,  C07K14/73 ,  A61K35/17

Abstract: Provided are a B-cell antibody receptor (BAR), a BAR-T cell and others which are effective for the treatment of diseases associated with antibodies produced in the bodies of patients. The B-cell antibody receptor (BAR) according to the present invention comprises (a) an antibody binding domain, (b) a transmembrane domain, (c) an intracellular domain of a costimulating factor and (d) an intracellular domain of an activated receptor which are linked together.